
Downloaded from: http://researchonline.lshtm.ac.uk/2031071/

DOI: 10.1097/QAI.0000000000000511

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
HIV-1 Transmissions During Asymptomatic Infection: Exploring the Impact of Changes in HIV-1 Viral Load Due to Coinfections

Rebecca F. Baggaley, PhD* and T. Déirdre Hollingsworth, PhD†‡§

Abstract: High HIV-1 plasma viral loads (PVLs) in sub-Saharan Africa, partly because of high rates of coinfection, may have been one of the drivers of the “explosive” epidemics seen in that region. Using a previously published framework of infectiousness and survival, we estimate the excess onward HIV-1 transmission events (secondary infections) resulting from coinfection-induced changes in PVL during asymptomatic HIV-1 infection. For every 100 HIV-infected people, each suffering 1 episode of tuberculosis infection, there are 4.9 (2.7th–97.5th percentile: 0.2–21.5) excess onward HIV-1 transmission events attributable to this coinfection. Other estimates are malaria 0.4 (0.0–2.0), soil-transmitted helminths 3.1 (0.1–14.9), schistosomiasis 8.5 (0.2–38.6), filariasis 13.3 (0.3–89.2), syphilis 0.1 (0.0–1.6), herpes simplex virus 4.0 (0.0–24.2), and gonorrhea 2.1 (0.1–8.0) transmissions. If these higher PVLs confer a shorter life expectancy and higher infectiousness, then their impact on transmission is, in general, reduced. For most HIV-1 coinfections, the duration of a single infection is too short and/or the associated PVL elevation is too modest to contribute substantially to onward HIV-1 transmission.

Key Words: HIV, transmission, viral load, tuberculosis, malaria, helminth, coinfections

INTRODUCTION

It has recently been suggested that high HIV-1 plasma viral loads (PVLs) in sub-Saharan Africa, partly as a consequence of high rates of coinfection, may have driven the “explosive” epidemics in that region. PVL is positively associated with heterosexual transmission, and systematic reviews have highlighted the increases in PVL that occur in the presence of various coinfections (tuberculosis (TB), malaria, schistosomiasis, other soil-transmitted helminth (STH) infections, filariasis, syphilis, herpes simplex virus (HSV), and gonorrhea) and/or the decreases in PVL when such coinfections are treated. It has therefore been proposed that treatment and/or prevention of these coinfections could reduce PVL and hence reduce HIV-1 transmission, in addition to the benefits of reducing the burden of these infections.

We have previously demonstrated that the small reductions in HIV-1 PVL observed in several randomized control trials of HSV treatment of HSV/HIV-1–coinfected individuals do not necessarily translate into substantial reductions in HIV-1 transmission. Indeed, depending on the distribution of PVLs within the population, small reductions in HIV-1 PVL may actually increase the total number of onward HIV-1 transmission events. This range of population-level outcomes is because of the spectrum of PVLs in a population, in response to treatment and the impact of PVL on survival and infectiousness. In general, individuals with high PVL are very infectious but have a relatively fast rate of CD4 decline and therefore a shorter HIV-1 asymptomatic period, whereas those with low PVL are less infectious but with a longer asymptomatic period, resulting in a longer window of opportunity for onward HIV-1 transmission.

Recent trials have shown that treating HSV/HIV-1 coinfection with acyclovir or valacyclovir reduces HIV-1 PVL, which may reduce infectiousness, and has now also been shown to decrease HIV-1 disease progression by decreasing the rate of CD4 cell count decline during asymptomatic HIV-1 infection. This delays the point at which antiretroviral therapy (ART) should be initiated but also provides more opportunities for onward HIV-1 spread. The impact of acyclovir/valacyclovir treatment on CD4 decline may be because of its reducing HIV-1 PVL but may also be because of its antiretroviral action reducing HIV-1 replication. However, because PVL is a major predictor of survival, it is plausible that reducing elevated PVLs because of other coinfections may have similar, if yet unquantified, effects.

Here, we apply our previously published framework, for the impact of changes in PVL on infectiousness and survival to estimate the public health impact of treating or preventing HIV-1 coinfections, and more generally, the
impact of interventions such as treatments or vaccines, which reduce HIV-1 PVL to a nonnegligible level to identify at what point such a reduction produces indisputable benefits, without potential deleterious effects on onward HIV-1 transmission. We explore 2 scenarios: (1) the increase in PVL on acquiring a coinfection increases infectiousness during the period of coinfection and (2) this PVL increase additionally reduces individuals’ projected durations of asymptomatic HIV-1 infection (by increasing the rate of CD4 decline).

METHODS

During the asymptomatic period of HIV-1 infection, the transmission potential of an infected individual is defined as the mean number of persons that 1 index case can infect over their whole asymptomatic period (the product of infectiousness and duration of asymptomatic infection). It is a function of set-point PVL (the PVL steady state reached after the peak PVL in early infection and before progression to AIDS). The concepts we explore are described by Baggaley et al and detailed in Figure 1 and the Supplemental Digital Content (http://links.lww.com/QAI/A619). Coinfection is assumed to increase HIV-1 PVL when acquired transiently during asymptomatic infection. We do not look at interactions between HIV-1 and coinfections during acute- or late-stage infection because these are periods where infectiousness changes rapidly and, in the case of acute infection, infectiousness may be far higher than would be predicted on the basis of PVL alone.

We assessed the impact of coinfections on HIV-1 transmission by modeling a hypothetical population of 10,000 individuals with varying baseline PVLs in a generalized HIV-1 epidemic in sub-Saharan Africa in the absence of ART. We used a frequency distribution of PVLs from a cross-sectional survey of young men in Orange Farm County, South Africa. We simulated varying shifts in PVL due to coinfections. Estimated elevations in PVL for each coinfection were sampled from distributions taken from published literature as listed in Figure 2 (for details of sampling, see Supplemental Digital Content, http://links.lww.com/QAI/A619). Durations of each coinfection were also taken from the literature (Fig. 2) and sampled from a uniform distribution of ±50% of the central value. All individuals in the model population experience an episode of coinfection, that is, results are not dependent on prevalence levels of each coinfection, and thus results do not represent any specific geographical area.

We looked at scenarios where the coinfection was acquired at the start and halfway through the asymptomatic period to explore the maximum impact of coinfection prevention, especially relevant for long duration infections such as HSV. We also explored coinfection-specific attributes such as coinfection-associated TB mortality and the possibility of multiple infection episodes per person for malaria and other macroparasitic infections.

We examined scenarios exploring 2 assumptions: (1) the increase in PVL on acquiring a coinfection increases infectiousness during the period of coinfection, and (2) this PVL increase additionally reduces individuals’ projected durations of asymptomatic HIV-1 infection (Fig. 1). We measured the change in the transmission potential due to this change in PVL. Transmission events attributable to each coinfection refer to direct transmission events from a coinfected individual (secondary infections).

The relationship between PVL and HIV-1 infectiousness estimated by Fraser et al shows a plateauing of

FIGURE 1. Schematic diagram illustrating the estimated impact of HIV-1 coinfections that increase HIV-1 PVL on (A) set-point PVL, (B) duration of asymptomatic HIV-1 infection, (C) HIV-1 transmission rate (hazard of transmission: probability of HIV-1 transmission per year), and (D) HIV-1 transmission potential (product of hazard of transmission and duration of asymptomatic infection) for 2 hypothetical patients. Time starts at the beginning of each individual’s asymptomatic period (ie, after high PVL accompanying primary infection). The individual with lower set-point PVL has a correspondingly longer duration of asymptomatic infection (A). The figure shows that all patients experiencing an increase in PVL as a result of coinfection would experience decreases in duration of asymptomatic infection and increases in HIV-1 infectiousness, but the direction of change to transmission potential depends on baseline set-point PVL and the amount that PVL is augmented on coinfection. See Baggaley et al for further explanation. The frequency distribution of set-point PVLs used in the analysis, based on a model fit to data from Orange County, South Africa, is shown in gray in (B–D) and shows that HIV-1–infected individuals with set-point PVLs typical of South Africa could have an increase or decrease in transmission potential as a result of modest decrease in PVL.
infectiousness at high PVL (Fig. 1C; also see Fig. 3a of Fraser et al, which demonstrates the plateau for Ugandan\textsuperscript{2} and Zambian\textsuperscript{data}). We explore the impact of this assumption by performing the analysis first using this plateauing function and then repeating the analysis using a widely used log-linear relationship estimated from the same Ugandan\textsuperscript{2} data: each log increment in PVL increases infectiousness by a factor 2.45 (see Fig. S2 for comparison of PVL-infectiousness relationships defined by Fraser\textsuperscript{9} and Quinn\textsuperscript{10}). The model was programmed and analyzed using Stata version 13.1 (StatCorp LP, College Station, TX).

RESULTS

Under the assumption that changes in PVL only affect infectiousness, for every 100 HIV-1–infected people, each suffering 1 episode of TB, there are 4.9 (0.2–21.5) excess onward HIV-1 transmission events attributable to TB coinfection (2.7th–97.5th percentile; Fig. 2). Excess onward HIV-1 transmissions for other coinfections are 0.4 (0.0–2.0) for malaria, 3.1 (0.1–14.9) for STH, 8.5 (0.2–38.6) for schistosomiasis, 13.3 (0.3–89.2) for filariasis, 0.1 (0.0–1.6) for syphilis, 4.0 (0.0–24.2) for HSV, and 2.1 (0.1–8.0) for gonorrhea. These represent coinfections acquired halfway through the HIV-1 asymptomatic period; coinfections acquired at the start of asymptomatic HIV-1 resulted in larger impacts for the longer duration infections only, such as HSV and filariasis (data not shown).

Under the assumption that changes in PVL due to coinfection affect both infectiousness and duration of infection, the impact of increased PVLs on transmission at the population is reduced (Fig. 2), with all the confidence intervals for number of HIV-1 transmissions crossing zero. In fact, HIV-1 transmission events attributable to coinfection are negative because the impact of increased infectiousness of individuals because of elevated PVL is outweighed by the reduction in survival also conferred by the higher PVL—there is less opportunity to transmit.

Long-lived infections with relatively large impacts on PVL, such as filariasis, conferred the most public health impact but also the greatest uncertainty in impact [filariasis: 1.2 (0.4–2.7) life-years lost per episode of coinfection compared with syphilis: 0.01 (0.00–0.09)]. Averting filariasis and schistosomiasis episodes may have a substantial impact in terms of life-years gained during HIV-1 asymptomatic infection, thus delaying time until ART is required. However, most coinfections are accompanied by too small an increase in PVL to have a substantial impact.

For the shorter lived infections, there is, of course, the possibility of multiple infections, which would increase their impact on PVL and transmission. Annual episodes of malaria infection, representing seasonality among the adult population, increased impact from 0.4 (0.0–2.0) HIV-1 transmissions attributable to 100 coinfection episodes to 2.4 (0.0–21.0) HIV-1 transmissions per 100 people who become infected with malaria annually over their entire duration of asymptomatic HIV-1 infection (results assume PVL change affects infectiousness but not survival). We did not consider endemic continuous infection with malaria or STH and schistosomiasis because endemic infection (ie, constant reinfection) would be rare among adults in high-intensity settings of sub-Saharan Africa, the majority of which would be among young children. Annual acquisition of gonorrhea throughout asymptomatic HIV-1 infection, representing extremely high-risk individuals, would lead to 12.1 (0.3–85.3) HIV-1 transmissions attributable to coinfection over the asymptomatic HIV-1 infection period of 100 people [estimates for syphilis: 0.4 (0.0–13.9) transmissions]. A more realistic level of 3 episodes over the asymptomatic HIV-1 period produces estimates of 6.2 (0.4–24.0) for gonorrhea and 0.3 (0.0–4.9) for syphilis.

We investigated the sensitivity of our findings to different assumptions regarding the PVL-infectiousness relationship. Using the PVL-infectiousness function defined by Quinn et al\textsuperscript{10} increased the impact of coinfections, predicting more onward HIV-1 transmission events per episode of coinfection (see gray plots in Fig. 2). This is because the Quinn function predicts higher infectiousness than the Fraser
function for a given PVL, but this may overestimate infectiousness (see Figure S2, Supplemental Digital Content, http://links.lww.com/QAI/A619).

**DISCUSSION**

For most HIV-1 coinfections, the duration of coinfection is too short and/or the PVL elevation too modest to reduce HIV-1 transmission or the duration of asymptomatic HIV-1 infection substantially. However, for longer duration infections such as HSV and filariasis, there may be benefit in averting or treating coinfection to delay time to HIV-1 treatment initiation, but the impact of coinfections and their treatment depends on the baseline HIV-1 PVL of the individual.

Scenarios incorporating the impact of TB-associated mortality during HIV-1 asymptomatic infection were investigated (methods and results available on request), which realized the intuitive outcome that life-years saved by preventing TB infection increased, whereas fewer onward transmission events were possible because a proportion of those dually infected would die before transmitting infection. Multiple episodes of coinfection within the same individual during asymptomatic HIV-1 infection increase impact. However, for coinfections where multiple infections are likely, such as malaria and gonorrhea, the PVL elevations per episode remain too small to generate a substantial effect, even when considering annual episodes.

Reductions in HIV-1 PVL can have positive or negative effects on transmission potential depending on individuals' baseline PVL and the effect on survival, for which there is biological plausibility but, as yet, limited empirical evidence. Mugwanya et al recently achieved a $>1 \log_{10}$ copies per milliliter reduction in HIV-1 PVL among HSV/HIV-1–coinfected individuals taking high-dose valacyclovir. However, a significant reduction in PVL is insufficient evidence of beneficial public health impact. Figure 2 suggests that such a reduction in HIV-1 PVL would reduce the overall onward HIV-1 transmission of individuals with asymptomatic infection, in the absence of ART, but the error bars indicate that for those with higher set-point PVL, a $1 \log_{10}$ copies per milliliter reduction would push them to higher transmission potential, not lower. Therefore, an intervention such as high-dose valacyclovir in the absence of ART would not be suitable for targeting to patients with high viremia. Although it may be cost saving in terms of delaying time at which point ART is required on clinical grounds, the potential for patients to transmit HIV-1 to their partners must also be taken into consideration, with suitable counseling and transmission-reducing interventions being essential to avoid negative effects on a longer timescale. Although the prospect of universal ART as treatment-as-prevention may leave this issue redundant, the trial results that will prove the success of this approach at the population level (rather than during clinical trials) are not yet in our hands, and with rationing of scarce resources, the use of lower cost treatments to delay the time of ART initiation may remain important. Our evaluation of the influence of coinfections on onward HIV-1 transmission among individuals not being treated for their HIV-1 infection remains informative because it would be premature to state that untreated undiagnosed HIV-1 infection is a thing of the past. For example, Public Health England estimated that in 2012, 22% of people living with HIV-1 in the United Kingdom, where there is relatively easy access to testing and treatment, were unaware of their infection.20 Our analysis relates to HIV-1 infectiousness during asymptomatic HIV-1 infection, an infection stage at which fewer patients are treated than during AIDS.

There are a number of limitations to our analysis. For example, the duration of infection for many of these infections may be longer for HIV-1–infected than for uninfected individuals. We could only make predictions for those coinfections where estimates of increases in PVL on coinfection are available in published literature. We also assumed no decrease in sexual activity as a result of coinfection, which would reduce numbers still further and therefore support our conclusion of limited impact of most coinfections on onward HIV-1 transmission events. Evidently, there is benefit to each individual of treating or curing each coinfection apart from the impact on their HIV-1 infection. Data on the duration of HIV-1 infection are from a population of Dutch homosexual men,21 whereas data underlying HIV-1 infectiousness assumptions are from Ugandan2 and Zambian populations. However, Fraser et al show a direct side-by-side comparison of survival rates between the Dutch seroconverters data set and a cohort of untreated female sex workers from Nairobi, Kenya, followed since seroconversion,22 which show very similar survival rates for individuals in similar PVL classes (see Figure S6, Supplemental Digital Content, http://links.lww.com/QAI/A619). Our assumption that changes in PVL affect survival is tentative, and we know that survival and rates of CD4 decline are affected by factors other than changes in PVL. For example, in Rakai, Uganda, subtypes A and D have very different survival profiles despite similar PVLs.23 Our analysis therefore presents outcomes with and without the assumption that changing PVL can alter HIV-1 disease progression. Our modeling framework does not use a population-level epidemic model of ongoing HIV-1 transmission; further investigation of the effect of coinfections on the time course of HIV-1 epidemics could be devised using dynamical epidemic models.

We have focussed on the long incubation period of HIV-1 infection, during which the PVL-infectiousness relationship holds.24 The effect of coinfection during symptomatic (late-stage) HIV-1 will likely be less, as individuals become less sexually active with disease progression. Coinfection during the high viremia accompanying acute infection may increase infectiousness even further, but we postulate the additional impact due to coinfections is small. The Fraser et al PVL-infectiousness model provides strong evidence of saturation of infectiousness at high PVLs (Fig. S2 and Fig. 3 of Fraser et al), so a half log augmentation due to coinfection would not markedly affect transmission. During acute infection, the PVL-infectiousness relationship is less clear: transmission rates have been shown to be significantly higher than would be expected on the basis of PVL (see Fig. 3 of Hollingsworth et al). Authors postulate that sexually transmitted infection (STI) coinfections may in part be
This relationship is less studied than that for PVL and acute HIV-1 virus phenotype may be more transmissible than that which evolves during incubation.

Our analysis focuses on the relationship between PVL and HIV-1 transmission, but an association between genital viral shedding and transmission has also been observed, independent of PVL. This relationship is less studied than that for PVL and is less reliable (Baeten et al found coinfection or intervention, which alters the PVL of HIV-infected individuals. Our results support the findings of previous studies, as well as the role of increased PVLs, due in part to coinfection. In the Rakai and Zambia studies, we found that PVL is the dominant predictor of transmission between discordant couples, and so it is currently the most suitable tool for measuring these effects.

Several research groups have recently suggested that increased PVLs, due in part to coinfection, are responsible for the large HIV-1 epidemics in sub-Saharan Africa. Our results suggest that some coinfections play a significant role, but it must be noted that although many of these coinfections are very prevalent in regions with high HIV-1 prevalence, they are not necessarily affecting those individuals who play a substantial role in HIV-1 transmission. For example, non-hookworm STIs such as Ascaris lumbricoides predominantly affect children. The association between HIV and these coinfections has been investigated by a number of authors, but data are rarely routinely collected in a way which would enable a population-specific estimate of the impact of these coinfections on viral load.

Our findings change markedly with the assumptions we make regarding the impact of changes in PVL on survival. The results presented here highlight the importance of understanding the relationship between PVL and duration of infection to estimate the population impact of any coinfection or intervention, which alters the PVL of HIV-1–infected individuals.

ACKNOWLEDGMENTS

The authors thank Brian G. Williams for providing additional data.

REFERENCES


Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.